Compare LAW & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LAW | CADL |
|---|---|---|
| Founded | 2013 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 466.2M | 280.3M |
| IPO Year | 2021 | 2021 |
| Metric | LAW | CADL |
|---|---|---|
| Price | $4.51 | $4.67 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $8.00 | ★ $18.50 |
| AVG Volume (30 Days) | 607.9K | ★ 1.3M |
| Earning Date | 05-25-2026 | 06-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 22.58 | ★ 58.62 |
| EPS | N/A | N/A |
| Revenue | ★ $156,849,000.00 | $125,000.00 |
| Revenue This Year | $11.23 | N/A |
| Revenue Next Year | $10.60 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 8.29 | N/A |
| 52 Week Low | $2.45 | $4.25 |
| 52 Week High | $9.11 | $9.08 |
| Indicator | LAW | CADL |
|---|---|---|
| Relative Strength Index (RSI) | 52.00 | 36.72 |
| Support Level | $3.92 | $4.57 |
| Resistance Level | $4.81 | $6.16 |
| Average True Range (ATR) | 0.39 | 0.23 |
| MACD | 0.22 | -0.01 |
| Stochastic Oscillator | 81.13 | 5.06 |
CS Disco Inc provides a cloud-native, artificial intelligence-powered legal solution that simplifies discovery, legal document review, and case management for enterprises, law firms, legal services providers, and governments. Its revenue-generating activities directly relate to the sale and support of legal solutions. It has two primary types of contractual arrangements: usage-based and subscription solutions. The usage-based revenue is derived from contracts under which customers are billed monthly based on their usage. Subscription revenue is derived from contracts where customers are contractually committed to a minimum data volume over a period of time.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.